CyBio and Axxam sign collaboration agreement for drug discovery using automated luminescence screening systems

09-Feb-2005

CyBio AG and Axxam srl have signed a contract to cooperate in the development and marketing of new technologies for drug discovery using automated luminescence screening systems.

With this agreement, CyBio combines its excellent detection and automation technology with Axxam's proprietary PhotinaTM assay technology for functional screening. CyBio brings to the collaboration the innovative CyBi® - Cellight System, an automated platform for the measurement of cellular processes built with the reliable and proven liquid-handling technology of CyBio and the new CyBi® - Lumax flash HT Reader. CyBi® - Lumax flash HT enables superior throughput and data quality in functional screenings.

With this cooperation, CyBio will extend its eminent competence in linking biological assays and detection technology. In combination with Axxam's assay technology, CyBio will generate new applications for CyBi® - Lumax flash HT and CyBio's automation technology. Axxam, with its PhotinaTM technology, will benefit from broader access to automated high-throughput screening (uHTS) and will expand its capabilities as an important provider of new assay technologies and services in drug discovery.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances